Introduction {#s1}
============

Cutaneous T-cell lymphoma (CTCL) represent a class of non-Hodgkin lymphomas of typically CD4+ skin-homing malignant T-cells. Mycosis fungoides (MF) is the most common subtype, manifesting clinically as cutaneous patches, plaques, and/or tumors. The accessibility of these lesions allows for skin-directed therapies. Characterized by significant immunogenicity, MF lesions further present the opportunity for local, immune-based treatment \[[@R1]\].

Recombinant human leukocyte interferon-α2 (rIFN-α2) is a systemic immunotherapy that has previously demonstrated therapeutic efficacy against CTCL, and a variety of other malignancies including other lymphomas, hairy cell leukemia, and chronic myelogenous leukemia \[[@R2]\]. Intralesional injection of rIFN-α2 has also been reported in a limited number of MF stage I and II patients, universally resulting in partial or complete resolution of the treated lesions both clinically and histologically \[[@R2]-[@R4]\]. These reports describe dosing of rIFN-α2 in the range of 1-2 MU per injection, three times weekly (3x/wk) for 4-12 weeks, often resulting in systemic side effects such as fevers, myalgias, nausea, and leukopenia \[[@R3]\].

Herein, we report two MF patients within whom intralesional injections of rIFN-α2 into refractory lesions were initiated at 0.5 MU 3x/wk, resulting in substantial clinical benefits without generalized side effects. Thereafter, increasing to 1.0 MU 3x/wk intralesionally resulted in complete resolution of treated lesions, also without the symptoms observed with the higher dosing of systemically administered rIFN-α2.

Report of Two Cases {#s2}
===================

Case 1: A 73-year-old man with stage IB (T1 N0 M0) MF was well-controlled for 8 years with a regimen of weekly narrow-band UVB (NB-UVB), topical bexarotene gel, topical mechlorethamine gel, and topical imiquimod to thicker lesions. However, the patient ultimately developed thick red-violaceous coalescing plaques on his left medial knee refractory to his treatment course ([Figure 1](#F1){ref-type="fig"}a).

The patient injected 0.5 MU of rIFN-α2b 3x/wk directly into the thickest lesions on his left medial knee. Starting from the perimeter, the patient delivered the intralesional rIFN-α2b in multiple injections rotating throughout the thickest lesions, distributing the medication as evenly as possible. This resulted in marked improvement over 8 months, with a \~75% reduction in size and thickness of the plaques, without any reported systemic symptoms. The dose was then increased to 1 MU of rIFN-α2b 3x/wk for 3 months, which induced complete resolution ([Figure 1](#F1){ref-type="fig"}b). While the patient reported mild fatigue with 1 MU dosing, this symptom completely resolved by moving the injections to the evening. Additionally, the patient did not require maintenance IM or SC injections of rIFN-α2b following the resolution of the injected lesions.

Case 2: A 64-year-old man with stage IIB (T3 N0 M0) MF was managed over a 2-year period with NB-UVB, oral bexarotene, topical imiquimod, and clobetasol, with good response except for localized, persistent lesions located on his back ([Figure 2](#F2){ref-type="fig"}a).

His persistent lesions were similarly treated with 0.5 MU of intralesional rIFN-α2b 3x/wk. After 3 months of treatment, the lesions had diminished in both size and thickness, resulting in several much smaller residual lesions. The remaining lesions on his back were then treated with 1 MU of intralesional rIFN-α2b 3x/wk which further improved their appearance and size, ultimately resulting in resolution ([Figure 2](#F2){ref-type="fig"}b).

Discussion {#s3}
==========

The clonal T-cells of MF produce IL-4 and IL-5 with diminished local levels of IL-12, IFN-γ, and IFN-α, thereby creating a cytokine imbalance that is both pro-inflammatory as well as inhibitory to anti-tumor immunity \[[@R5],[@R6]\]. Unregulated production of IL-10 and TGF-β seen in MF patients has also been hypothesized to diminish cell-mediated immunity, potentially contributing to the increased incidence of both infection and secondary cancers \[[@R5]\].

Directly, rIFN-α2 prevents tumorigenesis through the induction of cell cycle arrest, as well as both intrinsic and extrinsic apoptotic pathways \[[@R7]\]. Indirectly, the polypeptide inhibits angiogenesis, while modulating the immune antitumor response through the activation of cytotoxic T-cells and natural killer cells \[[@R8]\].

A glycoprotein rapidly degraded within the digestive tract, rIFN-α2 is administered intravenously, intramuscularly, or subcutaneously to achieve systemic levels. Intravenous rIFN-α2 has exhibited equivocal efficacy in MF stage IV patients and is less commonly utilized because of the rapid decline in serum concentration following administration \[[@R9]\]. Both intramuscular (IM) and subcutaneous (SC) administrations have demonstrated significant anti-tumor activity, resulting in partial or complete responses in MF patients at various stages of disease \[[@R9]\]. However, IM and SC delivery requires higher dosing for therapeutic efficacy, leading to considerable systemic toxicity and a constellation of dose-dependent side effects such as fevers, thrombocytopenia, leukopenia, and sepsis \[[@R9]\]. Studies with higher doses (\>30 MU IFN/week) given through IM injections necessitated dose reductions in as high as 50% of patients because of significant toxicity \[[@R10]\].

In response to these limitations, rIFN-α2 has also been delivered intralesionally ([Table 1](#T1){ref-type="table"}). Requiring lower doses to achieve plaque regression, intralesional rIFN-α2 has been recommended as a more tolerable alternative \[[@R9]\]. The doses of intralesional injection in prior reports ranged from 1-2 MU 3x/wk, with response times that varied from 4-12 weeks \[[@R2]-[@R4]\]. Several cohort pilot studies also reported beneficial effects in uninjected plaques, with improvement in distant lesions in as many as 7 out of 9 patients treated with intralesional rIFN-α2 \[[@R3]\]. Whether the response represented an abscopal effect and/or systemic immunostimulation is unclear. In one report, intralesional injection of rIFN-α2 reduced helper T-cell/suppressor T-cell ratios within treated lesions \[[@R3]\]. Moreover, three patients who had previously failed IM rIFN-α2 therapy experienced complete resolution of their lesions after initiating intralesional rIFN-α2 \[[@R4]\]. Although the incidence and severity of side effects were lower than those observed with high dose IM or SC injections, patients still experienced transient flu-like symptoms \[[@R2]\].

Our patients were initiated with 0.5 MU injections 3x/wk, resulting in substantial responses in injected lesions in the notable absence of systemic side effects. This experience suggests that initiation of intralesional rIFN-α2 at 0.5 MU per injection 3x/wk may be a well-tolerated therapeutic strategy in the management of MF.

Conclusion {#s4}
==========

MF is a cutaneous malignancy characterized by its chronic course and high rate of recurrence, thus presenting a significant challenge for therapeutic management. Our experience suggests that intralesional injections of rIFN-α2 at doses as low as 0.5 MU 3x/wk may be efficacious, and used safely in patients receiving other skin-directed and systemic therapies. Although further controlled, large-scale studies are required to investigate the efficacy of intralesional IFN, low-dose intralesional IFN may offer a well-tolerated option in the local immunotherapy of early-stage MF.
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###### The use of intralesional rIFN-α2 in the treatment of plaque-stage MF.

  **\# of Patients**   **Dose/Duration**                           **Stage**   **Response**                  **Reference**
  -------------------- ------------------------------------------- ----------- ----------------------------- ------------------------------------
  9                    2 MU (3x per week)                          I           3 CR, 6 PR                    Wolff *et al.* 1985 \[[@R3]\]
  6                    1 MU (3x per week)                          I, II       10 lesions CR, 2 lesions PR   Vonderheid *et al.* 1987 \[[@R2]\]
  3                    1 MU                                        I, II       2 PR                          Qiu *et al.* 1996 \[[@R4]\]
  1                    0.5 MU (3x per week) / 1 MU (3x per week)   I           CR                            This report
  1                    0.5 MU (3x per week) / 1 MU (3x per week)   II          CR                            This report

Key: CR (complete response), complete clinical remission (100% of lesions); PR (partial response), diminution of measurable disease (\>0% lesion resolution, but \<100%); SD (stable disease), no discernible change in lesions; PD (progressive disease), \>50% worsening of skin lesions. Stage I: T1/T2, N0, M0, B0/B1; Stage II: T1/T2/T3, N0/N1,N2, M0, B0/B1.

![Clinical findings on the left medial knee of a patient with stage IB MF. (**a**) Thick red-violaceous coalescing plaques before and (**b**) after treatment with intralesional rIFN-α2.](yjbm_93_1_41_g01){#F1}

![Clinical findings on the back of a patient with stage IIB MF. (**a**) Localized, thick persistent lesions before and (**b**) after treatment with intralesional rIFN-α2.](yjbm_93_1_41_g02){#F2}
